Renee Aguiar-Lucander, Calliditas CEO
Calliditas nabs accelerated OK for rare kidney disease, beating two competitors to the punch
Since its founding, Calliditas has wagered it could bring to market a new formulation of an oral steroid to treat a rare kidney disease. And …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
